What a laboratory knows about the material it receives
Every third-party report in this market describes a sample somebody chose to send. That choice is outside the laboratory’s control and outside its records.
Archive — January 2026
Page 3 of 5 of this archive, newest first.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
What a 17% rise in coupling-reagent prices does to a 30 mg vial
Follow the resin, not the catalogue.
Portugal caps semaglutide prescribing to 14 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
Escalating past the approved maximum, examined honestly
We looked at what the dose-ranging data supports about going higher, and it is thinner and less flattering than the market assumes.
Shanghai export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
Singapore declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Halvard & Pike Apothecary of Portland, Maine closes after 4 years
A proper account of an operation that existed, and of what closing it cost.
Custody, condition and the temperature nobody logged
Chain of custody, in a regulated setting, begins at sampling. Here it begins when the package arrives.
Why TFC can be entirely straightforward and still tell you nothing about bioburden
The Journal has read several hundred certificates from twenty companies. We set out what the documents actually cover, and what a reader is filling in from imagination.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
SURMOUNT-4 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The quiet end of the online reseller trading as Adamant Research Supply
A proper account of an operation that existed, and of what closing it cost.
Australia pharmacy body issues counselling standards for tirzepatide initiation
The evidence base is thin and the document says so, which is to its credit.
The supply gap as a clinical event
Cost is the modal reason for discontinuation in every dataset we have seen, and it is absent from the clinical literature.
What happens when the drug is taken away: three randomised answers
What was withdrawn, from whom, after how long, and what was measured afterwards.
Japan health authority warns on falsified liraglutide pens
Reported from the analysis, not from a warning notice.
Chengdu export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
A supplier suspends shipping to Nigeria after 19 consecutive customs detentions
The route did not close because of a rule about peptides.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
Two sessions a week, and the evidence behind the prescription
The recommendation survives scrutiny. The reasoning offered for it frequently does not.
The certificate says 2026. The vial in your hand does not say anything.
What happens to traceability when bulk material is subdivided, repackaged and relabelled two or three times before sale.
What changed at JEEP in January, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
The 21-day notice: how a compounding wind-down works in India
The document is four pages. Three of them are about dates.
Halvard & Pike Apothecary of Portland, Maine closes after 8 years
A proper account of an operation that existed, and of what closing it cost.
The ceiling is a tolerability finding, not an efficacy one
We looked at what the dose-ranging data supports about going higher, and it is thinner and less flattering than the market assumes.
Reading the receptor: what distinguishes cagrilintide from survodutide at the molecular level
A tour of what happens in the thirty seconds after binding, and why it matters at week thirty.
Repackaging, subdivision, and the batch number that changed hands
A document is only as good as the chain that connects it to the material, and most chains here are two or three links longer than the paperwork admits.
What the new South Korea guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
WXT declines, for the 16th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Spain health authority warns on falsified exenatide pens
Reported from the analysis, not from a warning notice.
South Korea caps tirzepatide prescribing to 24 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Calibrated, qualified, accredited: three words that are not synonyms
System suitability is the set of checks demonstrating that the instrument and method were performing adequately when your sample was injected. It is recorded as a matter of…
A shortage listing ends. 7 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
What a 23% rise in coupling-reagent prices does to a 20 mg vial
Follow the resin, not the catalogue.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
Inspectors cite the online reseller trading as Adamant Research Supply over sterility assurance
The observation that closes a facility is rarely the dramatic one.
What SURMOUNT-1 tells us about maintenance, and what it does not
Every withdrawal trial compared full dose against nothing. The clinically interesting comparison — full dose against a reduced one — has not been randomised.
What changed after we published the first version of this
None of what this piece asks for is commercially sensitive, and all of it is already known to whoever released the batch.